Investing News NetworkFebruary 21, 2024Topline Results Expected in Q2 2024This is a Designated News Release.Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ('Cardiol' or the 'Company'), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced completion of patient enrollment in its Phase II open-label pilot study ('MAvERIC-Pilot') investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis.

投资新闻网2024年2月21日计划于2024年第二季度公布业绩这是一份指定的新闻稿。Cardiol Therapeutics Inc.（纳斯达克：CRDL）（TSX:CRDL）（“Cardiol”或“公司”）是一家临床阶段生命科学公司，专注于抗炎和抗纤维化治疗心脏病的研究和临床开发，今天宣布完成其II期开放标签试点研究（“MAvERIC-pilot”）的患者登记，调查其安全性，CardiolRx™对复发性心包炎患者的耐受性和疗效。

In addition, the Company announced that it expects to report topline results from MAvERIC-Pilot in Q2 2024.'Having achieved full patient enrollment, we are now positioned to announce high-level MAvERIC-Pilot clinical trial data in the second quarter of this year. These results are expected to inform the design of a pivotal Phase III clinical trial in recurrent pericarditis to underpin the potential regulatory approval of CardiolRx™, which has recently been granted Orphan Drug Designation by the United States FDA,' said Andrew Hamer, Cardiol Therapeutics' Chief Medical Officer and Head of Research & Development.

此外，该公司宣布，预计将在2024年第二季度报告MAvERIC Pilot的topline结果。“我们已经实现了患者的全面登记，现在准备在今年第二季度公布高水平的MAvERIC Pilot临床试验数据。Cardiol Therapeutics首席医疗官兼研发负责人安德鲁·哈默（AndrewHamer）说，这些结果有望为复发性心包炎关键III期临床试验的设计提供依据，以支持CardiolRx™的潜在监管批准，CardiolRx™最近被美国FDA授予孤儿药称号。

'We thank our clinical collaborators and participating patients and families for their continued interest and commitment. Their support is contributing to our understanding of the therapeutic profile of CardiolRx™ in this debilitating inflammatory heart disease associated with symptoms that adversely affect quality of life and physical activity.' MAvERIC-Pilot (NCT05494788) is a Phase II open-label pilot study investigating the tolerance, safety, and effect of CardiolRx™ administered to patients with recurrent pericarditis.

“我们感谢我们的临床合作者以及参与的患者和家属的持续兴趣和承诺。他们的支持有助于我们了解CardiolRx™在这种与对生活质量和身体活动产生不利影响的症状相关的衰弱性炎症性心脏病中的治疗概况。”MAvERIC Pilot（NCT05494788）是一项II期开放标签试点研究，旨在研究CardiolRx™对复发性心包炎患者的耐受性，安全性和疗效。

The study has completed enrollment of the planned target of 25 patients i.

该研究已完成25名患者的计划目标登记。